Last month, PPD announced its plans to go public-the second time in its existence-filing its IPO for stock in January. Today, it began trading as PPD at $27 a share on the NASDAQ. PPD was founded in 1985 by Fred Eshelman, who took the company public in 1996. In 2011, it went private again with its purchase by The Carlyle Group and Hellman & Friedman.
For more information, click here.
Phase III Trial of Keytruda Plus Lynparza for NSCLC Stopped Due to Futility
December 7th 2023KEYLYNK-008 trial finds that Keytruda in combination with chemotherapy followed by Keytruda plus Lynparza did not produce an improved overall survival benefit in patients with metastatic squamous non-small cell lung cancer.
Key Phase III Trial Results Lead to FDA Approval of Fabhalta for Paroxysmal Nocturnal Hemoglobinuria
December 6th 2023Clinical trials demonstrated superiority of Fabhalta to anti-C5s in hemoglobin improvement in the absence of transfusions and transfusion avoidance rate, showing clinically meaningful hemoglobin-level increases without the need for blood transfusions in patients with paroxysmal nocturnal hemoglobinuria.